Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMHCA, a potent, selective LXR agonist, specifically activates the LXR pathway's cholesterol efflux arm, avoiding triglyceride synthesis stimulation. This compound exhibits anti-inflammatory properties and is utilized in researching cholesterol homeostasis and diabetes.
Description | DMHCA, a potent, selective LXR agonist, specifically activates the LXR pathway's cholesterol efflux arm, avoiding triglyceride synthesis stimulation. This compound exhibits anti-inflammatory properties and is utilized in researching cholesterol homeostasis and diabetes. |
In vitro | In ex vivo treatment of diabetic CD34+ cells, DMHCA (10 μM; 16-18 hours) effectively restores membrane fluidity to normal, non-diabetic levels and normalizes BM-derived TNF-α and IL-3 levels while significantly reducing CCL-2 production in both BM supernatants and systemic circulation by over 50% compared to control mice[1]. Additionally, DMHCA increases the number of circulating angiogenic cells (CACs) in both BM and peripheral circulation and promotes the release of vascular repair cells into the bloodstream[1]. Through PAGA analysis, it's evident that DMHCA treatment not only boosts the overall production of erythrocyte progenitors but also improves their robustness and flux, resulting in an increased density of erythrocyte progenitors in BM cells. Furthermore, DMHCA expands the proportion of these progenitors and elevates the expression of the hemoglobin beta adult chain (HBB-BT), underscoring its multifaceted role in enhancing erythropoiesis[1]. |
In vivo | Administered orally for six months at a dosage of 8mg/kg body weight per day in chow, DMHCA effectively restores cholesterol homeostasis in the retina of diabetic subjects. This action is marked by a significant elevation in the concentrations of endogenous LXR ligands, desmosterol, and total oxysterols within the diabetic retina[1]. |
Molecular Weight | 401.635 |
Formula | C26H43NO2 |
CAS No. | 79066-03-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DMHCA 79066-03-8 inhibitor inhibit